Developing Therapies that Change People's Lives

Brain Injury Outcomes

Johns Hopkins University
1550 Orleans Street
CRB-II, 3M50 South
Baltimore, MD 21231 USA
Office:   (410) 614-6996
Fax: (410) 502-7869
 
24-Hr: (410) 736-1368

Our Latest Clinical Trials

  • All
  • Active
  • Complete
  • Dizziness
  • Epilepsy
  • Stroke
  • TBI
  • Default
  • Title
  • Date
  • Random
  • MISTIE-II was a phase-II clinical trial across 32 clinical sites evaluating efficacy and long-term outcomes of thrombolysis in intracerebral hemorrhage (ICH). Results were presented at the 2013 International Stroke Conference.
    Read More
    • Complete
    • Stroke
  • CLEAR-III was an international 500-patient randomized clinical trial evaluating thrombolysis vs. medical management alone in the treatment of intraventricular hemorrhage. Enrollment in this ground-breaking trial completed in Jan-2015. Final results are expected in 2016.
    Read More
    • Complete
    • Stroke
  • MISTIE-III is a 500-patient, international multicenter clinical trial launched in 2013 to confirm the safety and long-term efficacy of thrombolysis in the treatment of intracerebral hemorrhage (ICH). The 5-year trial is funded by NINDS and was launched in Nov 2013. Up to 100 of the top stroke centers across the world are expected to participate in this 5-year project.
    Read More
    • Active
    • Stroke
  • ICES was the third tier in the MISTIE phase-II clinical trial. ICES evaluated minimally-invasive endoscopic removal of the intracerebral hematoma as a faster alternative to catheter-delivered intermittent thrombolytic therapy. The last patient completed in 2013. Publication of final results is forthcoming. Meanwhile, plans are underway for the next phase of this program.
    Read More
    • Complete
    • Stroke
  • EQUIGEN was comprised of two bioequivalency trials. The EQUIGEN Chronic Dose trial compared two disparate generics of lamotrigine. The EQUIGEN Single Dose trial compared branded lamotrigine with two disparate generics of lamotrigine for patients with epilepsy. BIOS served as the Coordinating Center for both trials.
    Read More
    • Complete
    • Epilepsy
  • CLEAR-IVH was a phase-II international trial enrolling 52 patients from 20 sites. It was completed in 2008. This study provided an early demonstration that treatment of IVH with catheter-delivered low-dose tPA can be safe and holds promise as a potential new therapy for intraventricular hemorrhage (IVH), a devastating form of hemorrhagic stroke.
    Read More
    • Complete
    • Stroke
  • HU Prevent is a multicenter placebo-controlled clinical trial of hydroxyurea in children with sickle cell disease. The goal is to determine if hydroxyurea can prevent brain injury and stroke. BIOS is the national coordinating center for this trial conducted at 25 clinical sites.
    Read More
    • Active
    • Stroke
  • SMARTS is a study conducted by Dr. John Krakauer exploring how the brain changes over the first year following a stroke. We are using several non-invasive techniques, including MRI, transcranial magnetic stimulation and measures of arm movement to learn more about how individuals recover from stroke.
    Read More
    • Active
    • Stroke
  • AVERT is a randomized multicenter clinical trial evaluating video-oculography (VOG), nystagmography and audiometry in patients presenting to an emergency department with dizziness and vertigo. The goal is a better treatment pathway with fewer misdiagnoses.
    Read More
    • Active
    • Dizziness
    • Stroke
  • POINT is a randomized, double-blind, multicenter clinical trial to determine whether clopidogrel (Plavix®) is effective in preventing major ischemic vascular events such as ischemic stroke and myocardial infarction in newly-diagnosed patients with TIA and minor ischemic stroke. BIOS is providing local coordination for the Johns Hopkins site.
    Read More
    • Active
    • Stroke
  • DIAS-4 is a phase III study, sponsored by Lundbeck, to evaluate the efficacy and safety of desmoteplase in study participants with acute ischemic stroke. It is a follow-on to the DIAS-3 study which completed in March-2014. BIOS (Brain Injury Outcomes Clinical Trial Coordinating Center) is acting as a local coordinating team for this study at Johns Hopkins.
    Read More
    • Active
    • Stroke
  • IVH Therapeutics is a clinical registry running on a mobile app to track worldwide adoption of the therapy and techniques that were evaluated during the CLEAR III clinical trial. It is hoped that this registry will help stroke researchers and scientists gain valuable information about the use of intraventricular thrombolytic therapy as it is generalized to community hospitals and specialized stroke centers around the world, many of which may not have participated in the clinical trial.
    Read More
    • Active
    • Stroke
  • BrainScope, one of our commercial clients, is conducting medical device trials in the field of traumatic brain injury. BIOS is serving as the Contract Research Organization, providing project management, electronic data capture, electronic trial master file, monitoring, training and general study support.
    Read More
    • Active
    • TBI
  • The Infrascanner-2000® was the world's first handheld medical device able to diagnose traumatic brain injury. BIOS served as the CT Reading Center for the pivotal trial run by Emissary International. The consistent, high-quality interpretation of computed tomography (CT) imaging was a key factor in gaining rapid regulatory approval of this innovative device.
    Read More
    • Complete
    • TBI